DMTK
| Market cap | $67.38M |
|---|---|
| Enterprise value | -$57.97 |
| Revenue | $15.664M |
|---|---|
| EBITDA | -$114.12 |
| Income | -$89.63 |
| Revenue Q/Q | 10.58% |
| Revenue Y/Y | 9.71% |
| P/E | 58.85 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | N/A |
| EV/EBITDA | 0.51 |
| EV/EBIT | 0.65 |
| PEG | N/A |
| Price/Sales | 4.30 |
| P/FCF | N/A |
| Price/Book | 1.18 |
| Book/Share | 0.13 |
| Cash/Share | 0.13 |
| FCF yield | -107.18% |
| Volume | 10.603M / 525.007k |
|---|---|
| Relative vol. | 20.20 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | 41.18% |
| Est. EPS Q/Q | 9.09% |
| Profit margin | -659.57% |
|---|---|
| Oper. margin | -588.62% |
| Gross margin | 1.80% |
| EBIT margin | -572.19% |
| EBITDA margin | -728.52% |
| Ret. on assets | -68.96% |
|---|---|
| Ret. on equity | -138.79% |
| ROIC | -62.28% |
| ROCE | -99.09% |
| Debt/Equity | 1.13 |
|---|---|
| Net debt/EBITDA | 0.39 |
| Current ratio | 3.53 |
| Quick ratio | 3.46 |
| Volatility | 35.58% |
|---|---|
| Beta | 1.65 |
| RSI | 17.98 |
|---|
| Insider ownership | 8.56% |
|---|---|
| Inst. ownership | 69.31% |
| Shares outst. | 30.215M |
|---|---|
| Shares float | 24.902M 82.42% |
| Short % of float | 11.83% |
| Short ratio | 3.56 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Thursday, 18 January 2024
|
|
| DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test Across All Skin Types | |
Thursday, 14 December 2023
|
|
| DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635 | |
Friday, 3 November 2023
|
|
| DermTech, Inc. Q3 2023 Earnings Call Transcript | |
Thursday, 21 September 2023
|
|
| DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635 | |
Monday, 11 September 2023
|
|
| DermTech Appoints Mark Aguillard as Chief Commercial Officer | |
Wednesday, 28 June 2023
|
|
| DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations | |
Wednesday, 10 May 2023
|
|
| DermTech, Inc. Analysts Just Slashed This Year's Revenue Estimates By 16% | |
Tuesday, 9 May 2023
|
|
| DermTech Appoints Bret Christensen as New President and CEO | |
Thursday, 13 April 2023
|
|
| DermTech Announces Release Date for First-quarter 2023 Financial Results | |
Tuesday, 7 March 2023
|
|
| DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test | |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| John Dobak (54) Chief Executive Officer and Director since 2019 | 54 | 2019 | $1,522,870 |
| Todd Wood (51) Chief Commercial Officer since 2019 | 51 | 2019 | $836,617 |
| Dr. John D. Dobak M.D. (55) Pres, CEO, and Director | 55 | $667,757 | |
| Burkhard Jansen (54) Chief Medical Officer since 2019 | 54 | 2019 | $480,829 |
| Kevin Sun M.B.A. (43) CFO, Treasurer, and Sec. | 43 | $378,152 | |
| Claudia Ibarra (59) Chief Operating Officer | 59 | $350,395 | |
| Matthew Posard | 2019 | $108,936 | |
| Scott Pancoast (61) Independent Director since 2019 | 61 | 2019 | $103,019 |
| Herman Rosenman (72) Independent Director since 2019 | 72 | 2019 | $101,996 |
| Gary Jacobs (62) Independent Director since 2019 | 62 | 2019 | $97,747 |
| Cynthia Collins (62) Independent Chairman of the Board since 2019 | 62 | 2019 | $89,690 |
| Enrico Picozza (60) Independent Director since 2019 | 60 | 2019 | $12,833 |
| Zuxu Yao (57) Chief Scientific Officer since 2019 | 57 | 2019 | |
| Claudia Ibarra (57) Chief Operating Officer since 2019 | 57 | 2019 | |
| Kevin Sun (40) Chief Financial Officer, Treasurer, and Secretary since 2019 | 40 | 2019 | |
| Daniel Visage | |||
| Todd Michael Wood (52) Chief Commercial Officer | 52 | ||
| Dr. Zuxu Yao Ph.D. (58) Head of Advanced Innovation | 58 | ||
| Dr. Burkhard Jansen M.D. (55) Chief Medical Affairs Officer | 55 | ||
| Ray Bassi | |||
| Ray Akhavan J.D. | |||
| Michael Howell Ph.D. |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
- Health Care > Life Sciences Tools & Services
- DermTech, Inc., 11099 North Torrey Pines Road, La Jolla 92037, United States
- 858 450 4222
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $31.046 | $40.209 | |||
| Short term investments | $11.4 | $19.123 | |||
| Net receivables | $2.497 | $2.584 | |||
| Inventory | $0.831 | $1.004 | |||
| Total current assets | $44.199 | $61.752 | |||
| Long term investments | |||||
| Property, plant & equipment | $55.304 | $56.71 | |||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | $58.771 | $60.178 | |||
| Total investments | $11.4 | $19.123 | |||
| Total assets | $102.97 | $121.93 | |||
| Current liabilities | |||||
| Accounts payable | $1.913 | $1.484 | |||
| Deferred revenue | $0.203 | $0.196 | |||
| Short long term debt | $3.211 | $3.086 | |||
| Total current liabilities | $12.518 | $13.447 | |||
| Long term debt | $50.458 | $51.308 | |||
| Total noncurrent liabilities | $50.458 | $51.308 | |||
| Total debt | $53.669 | $54.394 | |||
| Total liabilities | $62.976 | $64.755 | |||
| Stockholders' equity | |||||
| Retained earnings | -$443.945 | -$423.935 | |||
| Other stockholder equity | $0.184 | $0.178 | |||
| Total stockholder equity | $39.994 | $57.175 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $40.209 | $81.245 | ||
| Short term investments | $19.123 | $48.411 | ||
| Net receivables | $2.584 | $4.172 | ||
| Inventory | $1.004 | $1.757 | ||
| Total current assets | $61.752 | $136.037 | ||
| Long term investments | ||||
| Property, plant & equipment | $56.71 | $62.382 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $60.178 | $66.038 | ||
| Total investments | $19.123 | $48.411 | ||
| Total assets | $121.93 | $202.075 | ||
| Current liabilities | ||||
| Accounts payable | $1.484 | $2.419 | ||
| Deferred revenue | $0.196 | $0.109 | ||
| Short long term debt | $3.086 | $1.75 | ||
| Total current liabilities | $13.447 | $15.636 | ||
| Long term debt | $51.308 | $54.081 | ||
| Total noncurrent liabilities | $51.308 | $54.086 | ||
| Total debt | $54.394 | $55.831 | ||
| Total liabilities | $64.755 | $69.722 | ||
| Stockholders' equity | ||||
| Retained earnings | -$423.935 | -$323.047 | ||
| Other stockholder equity | $0.178 | -$0.774 | ||
| Total stockholder equity | $57.175 | $132.353 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $3.845 | $3.924 | |||
| Cost of revenue | $3.132 | $3.484 | |||
| Gross profit | $0.713 | $0.44 | |||
| Operating activities | |||||
| Research & development | $3.266 | $3.348 | |||
| Selling, general & administrative | $17.955 | $16.844 | |||
| Total operating expenses | $21.221 | $20.192 | |||
| Operating income | -$20.508 | -$19.752 | |||
| Income from continuing operations | |||||
| EBIT | -$20.01 | -$19.091 | |||
| Income tax expense | |||||
| Interest expense | |||||
| Net income | |||||
| Net income | -$20.01 | -$19.091 | |||
| Income (for common shares) | -$20.01 | -$19.091 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15.296 | $14.518 | ||
| Cost of revenue | $15.02 | $13.871 | ||
| Gross profit | $0.276 | $0.647 | ||
| Operating activities | ||||
| Research & development | $15.239 | $24.052 | ||
| Selling, general & administrative | $88.776 | $94.76 | ||
| Total operating expenses | $104.015 | $118.812 | ||
| Operating income | -$103.739 | -$118.165 | ||
| Income from continuing operations | ||||
| EBIT | -$100.888 | -$116.683 | ||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$100.888 | -$116.683 | ||
| Income (for common shares) | -$100.888 | -$116.683 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$20.01 | -$19.091 | |||
| Operating activities | |||||
| Depreciation | $1.406 | $1.346 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $2.697 | $3.151 | |||
| Total cash flows from operations | -$17.119 | -$12.707 | |||
| Investing activities | |||||
| Capital expenditures | $0.163 | ||||
| Investments | $7.834 | $12.08 | |||
| Total cash flows from investing | $7.834 | $12.243 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $0.126 | ||||
| Net borrowings | -$0.004 | -$0.024 | |||
| Total cash flows from financing | $0.122 | -$0.024 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$9.163 | -$0.488 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$100.888 | -$116.683 | ||
| Operating activities | ||||
| Depreciation | $5.846 | $4.46 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $18.565 | $18.934 | ||
| Total cash flows from operations | -$76.979 | -$95.26 | ||
| Investing activities | ||||
| Capital expenditures | -$0.902 | -$3.305 | ||
| Investments | $30.766 | -$1.014 | ||
| Total cash flows from investing | $29.864 | -$4.319 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.193 | $1.054 | ||
| Net borrowings | -$0.114 | -$0.137 | ||
| Total cash flows from financing | $6.079 | $0.917 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$41.036 | -$98.662 | ||
Sign up